Patient responses and multiple preclinical cancer models have demonstrated that healing effect of check-point blocking immunotherapy is closely related with the status and quantity of CD8 + T-cells.[32] Several literatures have demonstrated that CAF promote tumor growth, invasion and metastasis.[33] Immunotherapy-related biomarker analysis showed that the expression levels of immune check-point molecules such as CD274, HAVCR2, CTLA4, ICOS, and TIGIT were significantly upregulated in the low-risk group and cluster 2 compared with the high-risk group and cluster 1. Here, CD8A is linked to cancer.